Key facts
- Albus Health’s last known valuation is $11.1M (Dec 2024).
- It has raised $4.6M; the latest was Later Stage VC ($4.0M) in Dec 2024.
- Notable investors include Innovate UK, Creative Destruction Lab, Parkwalk Advisors, University of Oxford, Possible Ventures — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Albus Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Albus Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Albus Health
Developer of a non-contact respiratory monitoring system designed to provide personalized monitoring at home. The company's platform offers passive, contactless, and objective monitoring of a range of symptoms and environmental metrics at home, enabling pharma companies to generate more revenue from their drugs while de-risking, optimizing,g and scaling their clinical studies.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2017
- Employees
- 11
- Website
- albushealth.com/
- Ownership
- Privately Held (backing)
Albus Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Albus Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Albus Health in its N-PORT filings yet. We sweep new filings monthly.